New study asks: is fabry treatment worth it for seniors?
NCT ID NCT07277361
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
Fabry disease is a rare genetic condition that can cause pain, heart and kidney problems, and strokes. This study follows 100 people aged 65 and older with Fabry disease for 5 years, comparing those who receive specific treatment with those who do not. Researchers will measure quality of life using a standard questionnaire to see if treatment provides meaningful benefits later in life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If this study shows that treatment improves quality of life in older Fabry patients, it could help doctors decide whether to continue or start therapy beyond age 65.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other health factors common in older adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGED 65 YEARS OR OLDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Groupe Hospitalier Diaconesses Croix Saint-Simon
RECRUITINGParis, France, 75020, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early enzyme therapy save kidneys in fabry disease?
- Can continued lucerastat access help fabry patients?
- Can a single gene infusion rewrite the story of fabry disease?
- Text message nudge could save thousands from pneumonia
- Fabry disease sperm study halted early
- Heart study reveals hidden link between blood vessels and muscle blockage